NCT06026358撤回4 期
Tirbanibulin 1% Ointment for the Treatment of Actinic Keratosis on the Back of the Hands. An Internally Placebo Controlled, Partly Blinded Clinical Pilot Study
Medical University of Graz0 个研究点开始时间: 2023年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 撤回
- 发起方
- 主要终点
- Partial clearance at day 57 ± 7 after start of blinded treatment
研究概览
简要总结
Interventional, monocentric, national, internal placebo-controlled, prospective pilot study, consisting of two parts, A (single-blinded) and B (open) to assess Efficacy of Tirbanibulin for the treatment of AK on the back of the hand. In part A, eligible subjects receive Tirbanibulin on the left hand and placebo on the right hand for 5 d in a single-blinded manner. Safety and efficacy are assessed at day 8 (± 1 d) (3 days after the end of treatment (EoT+3) and day 57 (± 7 d) after the start of the treatment. Pictures will be taken at baseline, 8 d and 57 d (± 7 d) as per protocol and optional during unscheduled visits.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •o Informed consent
- •Diagnosed with AK on both hands
- •4-8 AK lesions on each hand, difference in number of lesions < 20%
- •Grade of lesions comparable in both hands: non hypertrophic, non-hyperkeratotic
- •Willing and able to comply with all study procedures
- •Use of medically acceptable contraception (both sexes)
- •18 - 99 years of age.
排除标准
- •o History of sensitivity and/or allergy to any of the ingredients in the study medication.
- •Open lesions of any kind on the hands
- •Concomitant cutaneous malignancy in treatment area
- •Immune deficiency
- •Participation in another clinical trial during the last 6 months
- •Had been previously treated with Tirbanibulin
- •Anticipated need for in-patient hospitalisation or in-patient surgery from Day 1 to Day
- •Treatment with 5-fluorouracil (5-FU), imiquimod, diclofenac, photodynamic therapy, or other treatments for AK within the treatment area or within 2 cm of the treatment area within 8 weeks prior to the Screening Visit.
- •Use of the following therapies and/or medications within 2 weeks prior to the Screening Visit:
- •Cosmetic or therapeutic procedures (eg, use of liquid nitro-gen, surgical excision, curettage, dermabrasion, medium or greater depth chemical peel, laser resurfacing) within the treatment area or within 2 cm of the selected treat-ment area
- •Acid-containing therapeutic products (eg, salicylic acid or fruit acids, such as alpha and beta-hydroxyl acids and gly-colic acids), topical retinoids, or light chemical peels within the treatment area or within 2 cm of the selected treat-ment area
- •Topical salves (nonmedicated/nonirritant lotion and cream were acceptable) or topical steroids within the treatment area or within 2 cm of the selected treatment area; artifi-cial tanners within the treatment area or within 5 cm of the selected treatment area.
- •Use of the following therapies and/or medications within 4 weeks prior to the Screening Visit:
- •Treatment with immunomodulators (eg, azathioprine), cy-totoxic drugs (e.g., cyclophosphamide, vinblastine, chlo-rambucil, methotrexate) or interferons/interferon induc-ers.
- •Treatment with systemic medications that suppress the im-mune system (e.g., cyclosporine, prednisone, methotrex-ate, alefacept, infliximab).
- •Use of systemic retinoids (e.g., isotretinoin, acitretin, bexaro-tene) within 6 months prior to the Screening Visit.
- •Skin disease (e.g., atopic dermatitis, psoriasis, eczema) or con-dition (e.g., scarring, open wounds) that, in the opinion of the investigator, might interfere with the study conduct or evalu-ations, or which exposed the subject to unacceptable risk by study participation.
- •Other significant uncontrolled or unstable medical diseases or conditions that, in the opinion of the Investigator, would have exposed the subject to unacceptable risk by study participa-tion.
- •Pregnancy or lactation
- •Excessive exposure to UV radiation during study period.
研究组 & 干预措施
Tirbanibulin
Experimental
Treatment
干预措施: Tirbanibulin (Drug)
Placebo
Placebo Comparator
Placebo
干预措施: Tirbanibulin (Drug)
结局指标
主要结局
Partial clearance at day 57 ± 7 after start of blinded treatment
时间窗: day 57 ± 7 after start of blinded treatment
次要结局
未报告次要终点
研究者
相似试验
已完成
4 期
Tirbanibulin 1% Ointment for the Treatment of Chronically Sun-damaged Skin on the FaceActinic KeratosisNCT05900258Medical University of Graz22
已完成
不适用
Tirbanibulin 1% Ointment in field therapy for the treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis on the face or scalp in adultsL57.0Actinic keratosisDRKS00027120Almirall Hermal GmbH549
已完成
3 期
A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic KeratosisKeratosis, ActinicNCT06135415Almirall, S.A.280
已完成
3 期
A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic KeratosisKeratosis, ActinicNCT05279131Almirall, S.A.105
终止
1 期
Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid MalignanciesAdvanced Solid TumorNCT04865159Kura Oncology, Inc.6